GC Biopharma announced on the 2nd that it has signed a contract with a major Pharmacy Benefit Manager (PBM) in the United States to list ‘Alyglo’ in their formulary. Alyglo is an immune…

Samsung Bioepis has announced that its biosimilar to Stelara, named ‘Pyzchiva’ (project name SB17, active ingredient ustekinumab), has received approval from the U.S. Food and Drug Administration…

Yuhan Corporation Receives Approval for Phase 1 Clinical Trial of Gaucher Disease Treatment Yuhan Corporation has taken its first step towards developing a treatment for a rare disease. The company…

A study demonstrating the superior efficacy of the combination therapy of Yuhan Corporation's non-small cell lung cancer (NSCLC) treatment, Leclaza (ingredient name: lazertinib), over the monotherapy…

Ahn Jae-Yong, CEO of SK Bioscience, highlighted the strategic importance of acquiring German contract manufacturing organization (CMO) and contract development and manufacturing organization (CDMO)…